NYSE · Healthcare · Drug Manufacturers - General
Price at previous close. Open the live page for real-time data.
| Market cap | $579.83B |
| P/E ratio | 27.993501554657794 |
| P/B ratio | 7.254739397309881 |
| P/S ratio | 6.01716809328366 |
| Dividend yield | 2.18% |
| Return on equity | — |
| Net margin | 21.8% |
| EPS (TTM) | — |
| Beta | 0.256 |
| 52-week range | $149.04 – $251.71 |
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division,…
What is Johnson & Johnson's P/E ratio?
Johnson & Johnson's trailing price-to-earnings (P/E) ratio is 28.0.
Does Johnson & Johnson pay a dividend?
Yes — the trailing dividend yield is approximately 2.18%.
What is JNJ's market capitalisation?
Johnson & Johnson's market cap is approximately $579.83B.
Educational data only — not financial advice. Figures from Financial Modeling Prep, updated periodically. Verify before acting.